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Abstract
Background
Several adult stem cell populations exhibit myogenic regenerative potential, thus represent-
ing attractive candidates for therapeutic approaches of neuromuscular diseases such as
Duchenne Muscular Dystrophy (DMD). We have recently shown that systemic delivery of
MuStem cells, skeletal muscle-resident stem cells isolated in healthy dog, generates the re-
modelling of muscle tissue and gives rise to striking clinical benefits in Golden Retriever
Muscular Dystrophy (GRMD) dog. This global effect, which is observed in the clinically rele-
vant DMD animal model, leads us to question here the molecular pathways that are impact-
ed by MuStem cell transplantation. To address this issue, we compare the global gene
expression profile between healthy, GRMD and MuStem cell treated GRMD dog muscle,
four months after allogenic MuStem cell transplantation.
Results
In the dystrophic context of the GRMD dog, disease-related deregulation is observed in the
case of 282 genes related to various processes such as inflammatory response, regenera-
tion, calcium ion binding, extracellular matrix organization, metabolism and apoptosis regu-
lation. Importantly, we reveal the impact of MuStem cell transplantation on several
molecular and cellular pathways based on a selection of 31 genes displaying signals specif-
ically modulated by the treatment. Concomitant with a diffuse dystrophin expression, a his-
tological remodelling and a stabilization of GRMD dog clinical status, we show that cell
delivery is associated with an up-regulation of genes reflecting a sustained enhancement of
muscle regeneration. We also identify a decreased mRNA expression of a set of genes hav-
ing metabolic functions associated with lipid homeostasis and energy. Interestingly,
PLOS ONE | DOI:10.1371/journal.pone.0123336 May 8, 2015 1 / 24
OPEN ACCESS
Citation: Robriquet F, Lardenois A, Babarit C,
Larcher T, Dubreil L, Leroux I, et al. (2015) Differential
Gene Expression Profiling of Dystrophic Dog Muscle
after MuStem Cell Transplantation. PLoS ONE 10(5):
e0123336. doi:10.1371/journal.pone.0123336
Academic Editor: Atsushi Asakura, University of
Minnesota Medical School, UNITED STATES
Received: September 24, 2014
Accepted: March 2, 2015
Published: May 8, 2015
Copyright: © 2015 Robriquet et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Raw data are available
via the EBI’s Array Express database under
accession number E-MTAB-2095.
Funding: This research was supported by grants
from the Association Française contre les Myopathies
(AFM N°14379) and the FEDER (Fonds Européen de
Développement Régional N°37085). It was carried
out in the context of the IHU-Cesti project that
received French government financial support
managed by the National Research Agency via the
investment of the future programme ANR-10-IBHU-
005. The IHU-Cesti project is also supported by
Nantes Metropole and the Pays de la Loire Region.
ubiquitin-mediated protein degradation is highly enhanced in GRMD dog muscle after sys-
temic delivery of MuStem cells.
Conclusions
Overall, our results provide the first high-throughput characterization of GRMD dog muscle
and throw new light on the complex molecular/cellular effects associated with muscle repair
and the clinical efficacy of MuStem cell-based therapy.
Introduction
Duchenne Muscular Dystrophy (DMD) is a progressive and fatal X-linked recessive disorder
of skeletal and cardiac muscles. It is the most common muscular dystrophy, affecting one in
3,500 male births [1], being characterized by a lack of dystrophin at the muscle fibre membrane
[2,3]. Dystrophin is the essential link between the subsarcolemmal cytoskeleton and the extra-
cellular matrix [4,5]. In dystrophin-deficient muscle, this connection is weakened and results
in the partial disruption of sarcolemma exposed to high tension and an influx of extracellular
Ca2+ that activates proteases. This leads to successive necrosis/regeneration cycles of the muscle
fibres, so that, ultimately, necrotic fibres fail to regenerate and the muscle tissue is progressively
replaced by connective and adipose tissue. Numerous observations suggest that the impaired
structural role of the dystrophin-glycoprotein complex alone may be insufficient to account for
the massive degenerative process and that the deregulation of intracellular signalling pathways
concomitant with skeletal muscle tissue remodelling also participate in DMD pathogenesis
[6–8].
Based on large-scale gene expression analysis, previous studies have described transcription-
al changes in the skeletal muscle of individuals with DMD. The first study revealed an over-ex-
pression of developmentally regulated genes such as α-cardiac actin and a down-regulation of
nuclear-encoded mitochondrial gene expression [9]. Another study suggested an up-regulation
of insulin-like growth factors and the induction of ‘cardiac-associated’ genes in dystrophin-de-
ficient muscle due to factors implicated in macrophage infiltration, activation of muscle satel-
lite cells and non-regeneration-linked changes in myofibre homeostasis [10]. It is also well
known that immune response signals and extracellular matrix genes, as well as genes encoding
muscle structure and regeneration processes, are over-expressed in DMDmuscle, thus reflect-
ing the regenerative nature of the disease [11,12]. In a more recent study, Pescatori et al. (2007)
described the gene expression signature that characterizes DMDmuscle during the initial or
presymptomatic phase of the disease, and showed the altered expression of genes involved in
the inflammatory response, remodelling of the extracellular matrix, muscle regeneration and
energy metabolism. Similar studies have been performed on themdxmouse, a genetic and bio-
chemical model of the human disease [13–16], confirming the presence of many alterations in
the dystrophic gene expression profile. Marotta et al. (2009) showed a strong up-regulation of
inflammation-related genes as well as genes related to cell adhesion, muscle structure/regenera-
tion and extracellular matrix remodeling duringmdx disease evolution [17]. More recently, a
transcriptomic study has been performed using a dystrophic dog model, CXMDJ, to analyse
dystrophic diaphragm tissue in the neonatal period [18]. Microarrays have also been described
as a useful tool to assess the effects of therapeutic approaches such as the antisense treatment,
or the overexpression of utrophin inmdxmouse [19,20]. To investigate potential therapies for
individuals with DMD, preclinical studies are commonly performed using the Golden
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Retriever Muscular Dystrophy (GRMD) dog model, which is characterized by rapid progres-
sive clinical dysfunction and severe muscle tissue remodelling [21,22]. GRMD dogs present
typical histological features of a dystrophic process with repeated cycles of muscle necrosis and
regeneration, variability in fibre size, splitting and fibrosis [23]. Moreover, GRMD dogs show
most of the signs found in the human disease, among themmuscle wasting, postural abnormal-
ities and premature death, allowing to consider GRMD dog as a relevant animal model for
DMD [22–25]. Recently, proteomic profiling performed on GRMD dogs have identified signal-
ling proteins implicated in secondary changes taking place in dystrophic muscles [6,26]. A
quantitative proteomic analysis, performed on both cytoplasmic and phospho-enriched frac-
tions, has identified 84 proteins as being differentially represented in GRMD versus healthy
dog muscle implicated in muscle development and contraction, glycolytic and oxidative metab-
olism, calcium ion homeostasis, intracellular signalling and regulation of apoptosis [6]. Never-
theless, little is known at present about transcriptional alterations affecting molecular pathways
in GRMD dogs. Indeed, only a single transcriptomic study has been carried out on GRMD
dogs aiming to define the molecular signals that drive muscle hypertrophy in Sartorius crania-
lismuscle and the differential muscle involvement in the GRMDmodel [27]. Recently, we have
shown that systemic delivery of MuStem cells, isolated using a modification of the procedure
that led to the identification of Muscle-Derived Stem Cells [28], could represent an attractive
avenue for future therapeutic applications in individuals with DMD. Indeed, when intra-arteri-
ally delivered in immunosuppressed GRMD dog, allogeneic MuStem cells contributed to mus-
cle damage course limitation with an increased regeneration activity and an interstitial
expansion restriction. Importantly, they allow persisting stabilization of dog’s clinical status de-
fined by a clinical score maintained up to 70% of that of the healthy dogs more than 6 months
after the cell transplantation, reflecting a poor fatigability, a low intensity of limb stiffness and
ankylosis [29]. These effects are linked to a relative low dystrophin protein level and a low per-
centage of dystrophin-positive muscle fibres that clearly evoke the implication of other molecu-
lar mechanisms to explain the mode of action of the MuStem cells. Since expression profiling
allows the simultaneous monitoring of a large number of biological processes, in the present
study we used an undedicated transcriptional approach with gene-expression microarrays to
analyse muscle samples from healthy, mock GRMD and MuStem cell-treated GRMD dogs
(GRMDMuStem). This strategy is reinforced by the fact that such an approach can detect
changes that are not histologically visible. We provide the first high-throughput characteriza-
tion of the GRMD dog model and report insights into the molecular/cellular impact of MuStem
cell delivery in a dystrophic context. Overall, we show that one remarkable outcome of MuStem
cell delivery concerns the up-regulation of genes implicated in regeneration of muscle fibre cor-
related with histological remodelling. In addition, we find that these cells can act on several
other biological pathways implicated in protein degradation mechanisms and energy
metabolism.
Materials and Methods
Animals
This study was approved by the Ethics Committee on Animal Experimentation of the Pays de
la Loire Region, France, in accordance with the guidelines from the French National Research
Council for the Care and Use of Laboratory Animals (Permit Numbers: CEEA.2012.104) (S1
Cheklist). Pain evaluation was performed every day during a complete clinical evaluation by a
veterinarian and an analgesia treatment was set up if necessary. Seventeen golden retrievers
were included in the study. All the dogs were obtained from the Centre d'Elevage du Domaine
des Souches (CEDS, Mézilles, France) and housed at the Boisbonne Centre for Gene and Cell
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Therapy of Oniris (Nantes, France). The dogs were housed in a controlled environment (tem-
perature 21 ± 1°C, 12-h light/dark cycle). GRMD dogs display a single base change in the ac-
ceptor splice site of intron 6 of the dystrophin gene. Skipping of exon 7 disrupts the mRNA
reading frame and results in premature termination of translation [30]. Affected dogs were
identified in the first week of life using polymerase chain reaction (PCR)-based genotyping.
This identification was confirmed by a dramatic and early rise in levels of serum creatine kinase
[31]. Seven 10-week-old healthy dogs were dedicated to MuStem cell isolation. The 10 other
dogs were used in the in vivo experiments at 9-month-old (3 healthy, 3 GRMD and 4
GRMDMuStem dogs) as described in Table 1. Among the 10 dogs, two dogs (#6G and #9GMu)
died before the end of the protocol at 38 weeks and displayed severe lesions of aspiration pneu-
monia after necropsy examination. Therefore, these animals are excluded from the transcrip-
tomic analysis because of their altered RNA profiles. One GRMDMuStem dog (10GMu) was
maintained alive for long-term follow-up. Dogs were euthanized by intravenous administration
of sodium pentobarbital (2000 mg, Dolethal, Vetoquinol SA, Magny Vernois).
Canine MuStem cell isolation
Primary wild type MuStem cells, corresponding to delayed adherent stem cells, were isolated
from a pool of hind limb muscles of 10-week-old dogs (n = 7; independent experiment) based
on a preplating technique, as previously established [29]. Cells were incubated at 37°C with 5%
CO2, maintained at roughly 75% of confluence to avoid spontaneous myogenic differentiation
and passaged every 4 to 5 days. The medium was replaced every two days to allow for their ex-
pansion. MuStem cells correspond to early myogenic progenitors and uncommitted cells char-
acterized by a large expansion capacity and an ability to differentiate into myogenic, osteogenic
and adipogenic cells after in vitro cell lineage-specific induction.
Immunosuppression of GRMD dogs
The mock GRMD (GRMD) and cell transplanted (GRMDMuStem) dogs were immunosup-
pressed with 27 mg/kg of oral cyclosporine (Neoral; Novartis, Rueil-Malmaison, France) ad-
ministered daily, in combination with 2.5 mg/kg azathioprine administered on alternate days
(Imurel; Glaxo-Welcome, Paris, France). A maximum of 10 mg/kg of ketoconazole (Nizoral;
Table 1. Description of the ten dogs used in the in vivo study.
Group Dog
identiﬁcation
Necropsy age
(weeks)
Immunosuppression MuStem cell
transplantation
Clinical scoring &
Histopathological analyses
Microarray RT-
qPCR
Healthy 1H 38 None None X X X
2H 41 None None X X X
3H 41 None None X X
GRMD 4G 41 CSA-AZA None X X X
5G 40 CSA-AZA None X X X
6G 38* CSA-AZA None X
GRMDMuStem 7GMu 40 CSA-AZA X X X X
8GMu 45 CSA-AZA X X X X
9GMu 38* CSA-AZA X X
10GMu Still alive CSA-AZA X X
The table presents a description of the Healthy, GRMD and GRMDMuStem dogs and gives details of the experiments carried out on each of the 10 dogs.
"*" signiﬁes that the considered dog died of aspiration pneumonia before the end of the protocol. "X" indicates that the considered experiment
was performed.
doi:10.1371/journal.pone.0123336.t001
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Janseen-Cilag, Issy-les-Moulineaux, France) was also added daily to decrease cyclosporine ca-
tabolism. Blood levels of cyclosporine were checked twice a week and cyclosporine doses were
consecutively adjusted to maintain an immunosuppressive level between 250 and 350 ng/mL.
The immunosuppressive regimen was started 1 week before the first cell administration, at an
age ranging from 14 to 16 weeks, and maintained until the dogs were euthanized.
Systemic cell delivery procedure
MuStem cell suspensions were prepared with a density range of 12 to 18x106 cells/mL in 0.9%
NaCl / 2.5% homologous serum / 10 U/mL heparin. Three injections of 6.5 to 23x107 MuStem
cells/kg, corresponding to two bilateral intra-arterial femoral injections and one injection into
the cardiac left ventricle, were performed on 4 GRMD dogs (referred to as GRMDMuStem: 7GMu
to 10GMu) aged initially from 15 to 17 weeks, using laminar flow at a rate of 15 mL/min, as pre-
viously described [29]. To carry out the intra-cardiac injection, a 5-French angiographic cathe-
ter (100 cm long; Launcher coronary guide catheter, Medtronic, Tolochenaz, Switzerland) was
advanced in a retrograde manner through the right carotid artery to the left ventricle. The ef-
fective crossing of the aortic valve with the catheter was assessed by appearance of a typical
ventricular pressure curve.
Clinical follow-up
Dogs were weighed and clinically assessed in a non-blinded manner by a D.V.M observer on a
weekly basis during all the experimental protocol. Blood samples were collected monthly and
hematological/serum biochemical testing were performed (S1 Fig). The clinical status of mock
GRMD and GRMDMuStem dogs was assessed weekly. A clinical score was measured following a
previously described method [29,32]. Briefly, the clinical score was established based on 11 lo-
comotion and muscular criteria and 6 items related to the general health status. It was express-
ed as the percentage of the maximum score defined as 100% for a healthy dog. Repeated-
Measures ANOVA were carried out from 10 to 39 weeks of age.
Muscle sampling
Biceps femorismuscle necropsies (0.5 cm3 fragments) were collected surgically from the middle
portion of the muscle in 9-month-old healthy (#H1 to #H3), mock GRMD (#4G to #6G), and
GRMDMuStem (#7GMu to #9GMu) dogs. Muscle biopsy was collected from the same muscle at 9
months of age from the #10GMu dog and used for histological analyses. This time point corre-
sponds to four months after systemic administration of cells into GRMDMuStem dogs. Muscle
fragments were divided into two parts for histological and molecular analyses, and subsequent-
ly archived at -80°C until processing.
Histology and immunohistochemistry
Transverse 8 μm-thick cryostat sections were stained with hematoxylin-eosin-saffron for histo-
pathological assessment. Sections were incubated (overnight, 4°C) with primary antibody
against dystrophin (1:50; NCL-DYS2, Novocastra) or the developmental isoform of myosin
heavy chain (MyHCd, 1:100; Novocastra). 488 Alexa fluor conjugated goat anti-mouse IgG
(1:300; Invitrogen) (1 h, room temperature (RT)) was used as a secondary antibody against
dystrophin. Immunofluorescence labelling was observed with a laser scanning confocal micro-
scope (Nikon C1; Champigny, France), and all acquisitions were performed as previously de-
scribed [29]. For MyHCd, the sections were incubated with biotinylated goat anti-mouse
(1:300; Dako) (1 h, RT) and streptavidin horseradish peroxidase (15 min, RT), which was
Muscle Profiling of MuStem Cell Treated GRMDDog
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revealed using DAB (3,3’-Diaminobenzidine) chromogen (10 min, RT). The sections were
counterstained with a DRAQ5 dye (Biostatus, Leicestershire, UK) to stain the nuclei. Histomor-
phometric analyses, including measurements of fibre diameter and number of MyHCd positive fi-
bres, were performed as previously described [29]. Mean fibre diameters were compared among
different dog groups with analysis of variance followed by Fisher PLSD tests. Percentages of
MyHCd+ fibres were compared between GRMDMuStem and mock GRMD dogs using a Mann-
Whitney test with a two-tailed P value. A value of P<0.05 was considered to be statistically signifi-
cant. For dystrophin labelling, all acquisitions were performed with the same signal amplification
resulting from identical detector gain value, as previously described [29]. To determine the pro-
portion of dystrophin+ fibres, 1,121±167 total fibres were counted by using differential interfer-
ence contrast in the Biceps femoris muscle sections of the GRMDMuStem dogs (n = 4) and
sequentially the number of fibres expressing dystrophin was determined by DYS2 green fluores-
cent immunolabelling.
RNA isolation
Total RNA was extracted from about 50 mg of frozen Biceps femorismuscle using the RNeasy
Fibrous Tissue Mini Kit (Qiagen, Santa Clara, CA, USA) according to the manufacturer’s in-
structions. Total RNA was quantified using a NanoDrop spectrophotometer (Nanodrop Tech-
nologies, Wilmington, DE, USA). Each sample was made up by pooling two independent
extractions of the same muscle and was then treated with DNAse Ambion (Life technologies,
CA, USA). RNA quality was assessed using the Agilent Eukaryote Total RNA Nano kit with
the 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA).
Canine gene expression microarray hybridization
The transcriptome experiment was performed by an Integrative Genomic Platform (Nantes,
France). mRNA expression profiling was obtained using the Agilent-021193 Canine (V2) Gene
Expression Microarray (Grid name: 021193_D_F_20120509- Protocol name: GE2_107_Sep09).
Microarray hybridizations were performed using standard operating procedures and quality con-
trols (Protocol: G4140-90050_GeneExpression_ Two_Color_v6.5-mai 2010). The labelling and
staining were performed according to the Agilent protocol. Briefly, 100 ng of RNA were ampli-
fied and stained with cyanine -5 or cyanine-3 dyes (4 samples were stained with cyanine cy5 and
4 others with cy3). Pairs of differentially labelled samples (2x825 ng) were hybridized on a slide
in 100 μL of hybridization buffer. After washing, the slides were scanned by the Agilent Scanner
(Agilent Technologies Scanner G2505C). Agilent Feature Extraction software (V 10.7.1.1) was
used to analyse the acquired array images.
Raw data preprocessing
The microarray expression data were pre-processed and analysed using the AMEN (Annota-
tion, Mapping, Expression and Network) suite of tools [33]. The data quality was checked
against QC reports from Feature Number Version 10.7.1.1. A background correction was per-
formed on the array data using the “normexp” method [34]. The microarray data quality was
verified by plotting the log2 signal distribution across samples. The median expression values
are considered for redundant probes. The array data of replicates were then normalized using
the “quantile-quantile” method. Replicate intensity values of healthy, mock GRMD and
GRMDMuStem samples were averaged.
Muscle Profiling of MuStem Cell Treated GRMDDog
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Expression data analysis
Statistical filtration and classification were performed for each pairwise comparison of the sam-
ples: mock GRMD versus healthy dogs, GRMDMuStem versus healthy dogs and GRMDMuStem
versusmock GRMD dogs. The detectable probes (22783/22841/22457) yielding signals7.32
(median of the normalized expression dataset) were first identified in each of the three respec-
tive comparisons. A total of 1074 (605/940/99) probes were further selected displaying a high
expression variation (fold-change, FC2.0). A LIMMA statistical test [35] was then performed
to identify 608 (430/567/41) probes that were significantly differentially expressed (F-value ad-
justed with the False Discovery Rate, p0.05). For each of the three comparisons, the selected
probes were finally classified into two groups (based on the fold-change), named “up” or
“down” according to their expression profiles.
Canine gene and probe annotation
To obtain the most complete annotation possible, we considered the dog annotation based on
the Entrez Gene IDs (NCBI) provided in the AMEN suite of tools [33], and then supplemented
with the Ensembl annotation. The microarray probes were subsequently mapped on the can-
Fam3 genome using the BLAT program [36]. To filter the alignments, we considered a percent-
age of identity of90% over the whole size of the probes (60 bps). The probes were further
associated with canine genes based on their genome coordinates and the overlap with exonic
regions of annotated loci. It is noteworthy that a given probe can be assigned to several genes,
while several probes can be associated with a single gene.
Gene Ontology enrichment analysis
The enrichments of annotation terms within a group of genes were calculated with the Fisher
exact probability using a Gaussian Hypergeometric test. A Gene Ontology (GO) term is consid-
ered to be significantly enriched when the number of genes bearing this annotation is3 and
when the associated FDR-corrected p-value is0.005 for biological process terms and0.01
for terms related to the biological function and cellular component categories.
Microarray data repository
Raw data CEL files are available via the EBI’s Array Express database (www.ebi.ac.uk/arrayexpress)
under accession number E-MTAB-2095 [37].
Comparison with transcriptomic studies of individuals with DMD
The group of genes significantly deregulated in muscle of individuals with DMD was extracted
from four studies [8,9,11,12]. The conversion of the Affymetrix human probe set identifiers
into dog NCBI Entrez Gene identifiers was performed with the AMEN suite of tools via the
HomoloGene database [38] and the array annotations provided by the AILUN annotation plat-
form [39]. A group of human genes is taken as significantly associated with a group of dog
genes if the associated p-value is0.005 (Hypergeometric test).
Quantitative RT-PCR for validating Agilent dataset
The RT-qPCR validations were done on the three healthy dogs (#1H to #3H), on two mock
GRMD dogs (#4G and #5G), on two GRMDMuStem dogs (7GMu and 8GMu). Additional RT-
qPCR experiments were also performed on muscle total RNA from two non-immunosup-
pressed GRMD dogs (referred to as GRMDnonIS) kindly provided by collaborators.
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A subset of genes was selected to validate the data obtained by microarray analysis. Reverse
transcription reactions were carried out on 0.5 μg of total RNA using the GoScript reverse tran-
scriptase (Promega, Madison, USA) in a total volume of 20 μL. All cDNA amplifications were
performed, in duplicate or triplicate, using 1/20th of the reverse transcription products and the
MESA BLUE qPCR kit (Eurogentec, Seraing, Belgium). Quantitative PCR was run on the Ther-
mocycler CFX96 (Biorad, California, USA) with the following parameters: 5 min at 95°C for
the initial denaturation step, then 15 sec at 95°C, 1 min at 60°C per cycle, for a total of 40 cycles.
The specific amplification was checked using a melting curve. Gene-specific oligonucleotide
primers were designed using Oligo Primer Analysis Software v.7 (Molecular Biology Insights
Inc., Cascade, USA) and synthesized by Eurofins MWGOperon (Ebersberg, Germany). The
primers used are listed in Table 2. RPS18 was selected as an endogenous control. The relative
expression levels were calculated by the 2-ΔΔ Ct method.
Results
Clinical follow-up of GRMD dogs
Our previous results demonstrated the capacity of wild-type MuStem cells to reach muscle tis-
sue and generate clinical benefit following repeated injections into the left femoral artery of
GRMD dogs [29]. Here, we reproduce the cell delivery protocol using a 6.5- to 23-fold increase
in cell number and performing two bilateral intra-arterial femoral injections combined with an
injection into the cardiac left ventricle of four immunosuppressed GRMD dogs. Mock dogs dis-
play a progressive clinical impairment as assessed by their clinical score (mock GRMD dogs;
#4G to #6G) (Fig 1A). The clinical score is expressed as a percentage of the maximum score de-
fined as 100% for a healthy dog. After a dramatic decrease of their ambulatory abilities from 14
to 20 weeks of age, their clinical score stabilizes at 56.7±21.2% at 38 weeks. This standard devia-
tion illustrates the great variability in their clinical course as previously described [40]. All
GRMD dogs that received MuStem cells (GRMDMuStem dogs; #7GMu to #10GMu) display an
early and persistent stabilization of their clinical score that was maintained at 77.8±5.4% at 38
weeks (9 months of age) (Fig 1A). Repeated-Mesures ANOVA carried out from 10 to 38 weeks
Table 2. Sense and anti-sense primer sequences used for validation of quantitative real-time PCR expression.
Gene name Transcript accession Sense primer (5’-3’) sequence Anti-sense primer (5’-3’) sequence Product size (bp)
ACTC1 XM_535424.4 GGTGGGAATGGGACAGAAGG TCACGGTTGGCCTTAGGGTT 219
ADIPOQ NM_001006644.1 GAGATGGCACCCCTGGAGA CCCCACACTGAATGC CGAAC 182
DEPTOR XM_539149.4 CAGACCGGGGCATCATTCA TTGACCCCTTCCTCTTCCCT 202
FBXO32 XM_532324.4 GACAAAGGACAGCTGGATTGGA TCTCCGTACTGCTCTTTCCGTG 77
FLRT2 XM_005623720.1 GAGCTGCGAGTGGACGAAAA AGGTTTGAGAAGGCCGTCAG 275
GATM XM_544663.4 AAGTGATAGTGGGCAGAGCAG GGGAAAATAGTGGCCTCCGTG 119
GPD1 XM_845287.2 AAGGACCAGACCCAAGGAC AAGGCCCCACAGATCTCCA 104
HFE2 XM_854431.2 TGCTGGGGTTCCTCTTTCCT CTTCCCTGTCTCTAACCCCT 139
MUSTN1 XM_005642250.1 TCGTACAGCACCCACCATGTC TTCACACTCCCGCATGACC 160
NRBF2 XM_005618923.1 GGAAAAGGGCAAAGCGGGA TGGAAGGGCTGTATTTCTCGG 147
PPP1R3B XM_539996.3 TCGGTGTTCCTACGGTCTGTTC CTTCCATCTCCACCTGCCT 135
PVALB XM_003431505.1 CTTTACCGCTGTCGACTCCTT TCTTGCCATCCCCGTCCTT 239
RPS18 NM_001048082.1 CTAGTGATCCCTGAGAAGTTCC ATGTCTGCTTTCCTCAATACC 143
SPP1 XM_003434023.2 CCAGCAACCCAATTATTCACTCC GGGAAAGTAGGACGGCATTGAAG 205
ST3GAL5 XM_005630478.1 AGCACAGGTACAGCACGGA TCTCAAGTGTTCGGGCATGT 164
ZFAND5 XM_005615855.1 AGAGGCAGCAGAATAGTGG AAACTGATGGACTGGGCTG 279
doi:10.1371/journal.pone.0123336.t002
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of age indicate a significant effect of the MuStem cell delivery (F = 601.5; p<0.001) and the in-
dividual GRMD dog (F = 143.9; p<0.001), as well as an interaction between cell delivery and
time (F = 3.7; p<0.001). General posture and stance are the most obvious corrected criteria in
GRMDMuStem dogs (Fig 1B and 1C representing #7GMu and #4G, respectively). Overall, these
data demonstrate that combined intra-femoral injection and cardiac ventricle deposit allow
global and persistent improvement of the GRMD dog clinical status.
Tissular impact of MuStem cell delivery
Histopathological analyses of skeletal muscles from all GRMD dogs show a typical dystrophic
pattern including size variation among individual muscle fibres, individual fibre necrosis and
calcification foci, as well as small regenerating basophilic fibres, numerous fibres with centrally
located myonuclei and significant replacement of muscle tissue by connective tissue and, to a
minor extent, adipose tissue (Fig 2A and 2B). Histomorphometry analysis was performed on
the Biceps femorismuscle of 9-months aged healthy dogs (#1H to #3H), mock GRMD dogs
(#4G to #6G) and compared to GRMDMuStem dogs (#7GMu to #10GMu). Based on the mini-
mum Ferret diameter, we show that the mean fibre diameter is not discriminant between the
groups (42.4±13.8, 34.8±16.8 and 33.0±14.2 μm for healthy, GRMD and GRMDMuStem dogs,
respectively). The variation coefficients associated with fibre diameter measurements (32.4,
48.3 and 42.9%, respectively) highlight the decreased anisocytosis observed in GRMDMuStem
dogs compared to mock GRMD dogs (p<0.0001). Regenerative activity in the same samples is
also assessed using a specific MyHCd labelling (Fig 2D–2F). No MyHCd+ fibre are observed in
healthy dog muscles. While 4.8±2.4% of fibres express this developmental isoform in mock
GRMD dog muscles, the proportion of MyHCd+ fibre in GRMDMuStem dogs is 18.7±9.5%,
demonstrating an increase in muscle regenerative activity following MuStem cell delivery
(p<0.001). Immunofluorescent labelling of dystrophin in the Biceps femorismuscle shows no
expression of this protein in mock GRMD dogs, apart from some rare positive fibres corre-
sponding to revertant fibres. On the other hand, isolated or clustered dystrophin+ fibres are
scattered throughout the whole muscle section of GRMDMuStem dogs. These fibres,
Fig 1. Clinical follow-up. (A) Mean±SD clinical scores of mock GRMD dogs and MuStem cell-injected dogs (GRMDMuStem). The clinical score of each
GRMD dog was assessed weekly and expressed as a percentage of a theoretical healthy dog score. Limits of the MuStem cell delivery window are indicated
(dashed lines). (B) Right lateral view of a GRMDMuStem dog, #7GMu. (C) Right lateral view of mock GRMD dog, #4G. Note the anterior weight transfer
and plantigrady.
doi:10.1371/journal.pone.0123336.g001
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corresponding to 25.0±3.9% of all fibres, are characterized by a global low expression level
compared to that observed in healthy dog muscle and by a continuous or discontinuous label-
ling along the membrane (Fig 2G–2I and S2 Fig). A nuclear counterstaining and bright field-
image allow us to visualize all the fibres in the muscle cryosection (S3 Fig). Altogether, we dem-
onstrate histological remodelling of the GRMD dog muscle following MuStem cell delivery, in-
cluding a boost in its regenerative capacity, which is consistent with the clinical impairment
observed in the GRMDMuStem dogs and a low-level expression of dystrophin in scattered fibres.
Sample quality controls
The quality of total RNA samples was checked on the Agilent 2100 bioanalyzer. The electro-
pherogram of the six samples corresponding to two healthy dogs (#1H, #2H), two mock
GRMD dogs (#4G, #5G), and two GRMDMuStem dogs (#7GMu, #8GMu), shows an absence of
Fig 2. Histological analysis of the Biceps femorismuscle of 9-month old dogs.Healthy (#3H), GRMD (#6G), and GRMDMuStem (#7GMu) dog muscles
are presented respectively in left, mid and right panel. (A, B, C) Muscle tissue presentation after hemalun eosin safran staining. (B) Mock GRMD dogs display
a typical dystrophinopathic pattern with diffuse anisocytosis, hypertrophic hyaline fibres (open arrowhead), centronucleated fibres (arrow), necrotic fibres (*),
regenerative foci (black arrowhead) and multifocal thickening of the endomysial space by fibrosis (highlighted by the saffron yellow staining). (C) The
dystrophinopathic pattern is remodelled in GRMDMuStem dogs: anisocytosis is milder, hypertrophic hyaline fibres and necrotic fibres are less numerous,
whereas centronucleated fibres are more abundant (arrow) compared to GRMD dogs. Inset, another picture taken on the same tissue sample with a higher
magnification that displays centronucleated fibre. (D, E, F) Regenerative activity of muscle fibres in healthy, GRMD and GRMDMuStem dogs, as indicated after
immunolabelling specific to the developmental isoform of the myosin heavy chain (MyHCd). (G, H, I) Dystrophin expression in healthy, GRMD and
GRMDMuStem dogs. (A-B-C; G-H-I) Scale bar = 200 μm (in set Scale bar = 100 μm). (D, E, F) Scale bar = 500 μm.
doi:10.1371/journal.pone.0123336.g002
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degradation products in parallel with high RNA Integrity Numbers (RIN), validating the quali-
ty of all initial RNAs (S4A Fig). The canine gene expression microarray data reveals a homoge-
nous signal intensity distribution across the samples (S4B Fig). The dendrogram plotted from
the distance matrix of the overall expression signals shows that the healthy samples are
grouped together, revealing the proximity between the mock GRMD and GRMDMuStem dog
samples (S4C Fig).
High-throughput characterization of GRMD dog model
The statistical filtration and classification (Fig 3) allows the identification of 282 genes (corre-
sponding to 430 probes) differentially expressed between healthy and GRMD dogs, thus pro-
viding a high-throughput characterization of the GRMD dog model. Thus, 218 genes (321
probes) and 64 genes (109 probes) are identified as significantly up-regulated and down-regu-
lated, respectively (S1 File.).
A comparison with human studies shows that, among the 282 genes differentially expressed
between the GRMD and the healthy samples, 117 genes have been previously identified as dif-
ferentially expressed in individuals with DMD in at least one of the studies considered
[8,9,11,12]. Interestingly, out of these 117 genes, 98% are either up- or down-regulated in both
Fig 3. Flow chart of the statistical filtration of microarray data. Procedure leading to classification for each of the three pairwise comparisons of healthy,
GRMD and GRMDMuStem dog muscle samples.
doi:10.1371/journal.pone.0123336.g003
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the GRMD dog model and the DMD patient. As reported in Table 3, among the genes that are
common between our dataset and the human transcriptomic studies, we can identify signifi-
cant enrichments of genes that are up-regulated or down-regulated in both canine and human
studies.
The GO terms significantly enriched in the group of genes differentially expressed between
GRMD dog and healthy dog muscle are determined [41] (Fig 4 and S2 File). Among the genes
up-regulated in GRMD dog as compared to healthy dog, we find enrichment for processes
such as immune system process (n = 49, p<2x10-5), inflammatory response (n = 17, p<2x10-4),
response to stimulus (n = 126, p<7x10-6), response to stress (n = 75, p<2x10-4), response to lipid
(n = 28, p<4x10-4), regeneration (n = 11, p<2x10-3) and cell adhesion (n = 27, p<2x10-4). Cal-
cium and energy metabolism as well as extracellular matrix disorders are also represented by
the enrichment of calcium ion binding (n = 25, p<5x10-5) and extracellular matrix organiza-
tion (n = 22, p<7x10-8) in the up-regulated group of genes. The down-regulated group is sig-
nificantly enriched in genes associated with terms involved in oxidation-reduction processes
(n = 23, p<6x10-10), regulation of transmembrane transporter activity (n = 5, p<5x10-3),mito-
chondrion (n = 29, p<7x10-11) and fatty acid beta-oxidation (n = 6, p<4x10-4). Furthermore,
five genes involved in apoptosis regulation are noted among the group of genes which are up-
regulated and involved in the regulation of protein secretion (n = 9, p<5x10-3). Also, we detect
an enrichment of themembrane-bounded vesicle (n = 34, p<7x10-5) term in the group of up-
regulated genes in GRMD dog muscle as compared to healthy dog.
Impact of MuStem cell delivery on GRMD skeletal muscle
Thirty one genes (41 probes) are identified as differentially expressed as a consequence of MuS-
tem cell administration (Fig 3). Sixteen genes (21 probes) are significantly up-regulated in
GRMDMuStem dog muscle as compared to mock GRMD dog. Their expression profile shows a
global tendency to increase in mock GRMD dog samples as compared to healthy dog (Fig 5A).
A significant down-regulation of expression is identified for 15 genes (20 probes) in
GRMDMuStem as compared to mock GRMD dog muscle. Among these 31 genes, 8 show a slight
decrease of expression in GRMD samples as compared to healthy samples, followed by a
marked decrease in GRMDMuStem samples, while some other genes such as ST3GAL5, GATM
or PSMB9 exhibit an increased expression in GRMD samples as compared to healthy sample
followed by a significant decrease in GRMDMuStem samples.
Table 3. Comparison with human studies.
GRMD versus Healthy
Up-regulated Down-regulated
Chen et al., 2000 Up-regulated 51 (2.9x10-20) 1
Down-regulated 1 8 (4.9x10-3)
Haslett et al., 2002 Up-regulated 27 (3.6x10-21) 0
Down-regulated 0 3 (3.9x10-4)
Haslett et al., 2003 Up-regulated 14 (9.4x10-7) 0
Down-regulated 0 0
Pescatori et al., 2007 Up-regulated 76 (2.5x10-44) 0
Down-regulated 0 15 (2.3x10-11)
The number of genes that are signiﬁcantly up- or down-regulated in this dog model and in the human study are indicated. These numbers are followed by
the corresponding p-value given in parentheses when a signiﬁcant enrichment is detected.
doi:10.1371/journal.pone.0123336.t003
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The number of genes in these expression patterns is too small for a GO statistical analysis.
Nevertheless, it is noteworthy that we can identify genes involved in processes such asmuscle
regeneration, cellular homeostasis as well asmetabolism. Thus, the activation of satellite cells
(MUSTN1) and muscle regeneration (SPP1, MYH3/MYH8, DEPTOR, KLHL31 and PSMB9)
are affected by MuStem cell delivery, in parallel with genes involved in protein degradation,
protein folding (FBXO32, TRIM63, ZFAND5 and MT2A) and the anti-apoptosis pathway
(MCL1, AMIGO2). Two genes (PVALB and AQP4) are implicated in cell homeostasis and
Fig 4. Functional characterization of GRMD dogmodel. A selection of Gene Ontology (GO) terms
significantly enriched in the groups of genes up- and down-regulated between GRMD dog model and healthy
dog. Associated with the GO term, the total numbers of genes assigned with this annotation are indicated,
followed in the rectangle by the number of genes observed (on left) and expected by chance (on right).
Numbers in bold indicate a significant over-representation of the corresponding GO term. Enrichments are
colour-coded according to the associated p-value from red (enriched) to blue (depleted).
doi:10.1371/journal.pone.0123336.g004
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calcium / water homeostasis, respectively. In terms of metabolism, two genes (ST3GAL5,
GPD1) related to lipid metabolism are down-regulated. ADIPOQ represents a third example of
the down-regulation of lipid metabolism. This latter gene is significantly up-regulated in
GRMD dog muscle as compared to healthy dog, and has a tendency to be down-regulated in
GRMDMuStem dog (FC -1.57). Five other genes play a role in glucose metabolism (AMPD3,
DEPTOR, GATM, PFKFB1 and PPP1R3B).
Real-time quantitative PCR validation of array results
To validate the related microarray data, we chose 15 of the 31 differentially expressed genes in
the GRMDMuStem dog group compared to mock GRMD dog (Fig 5A) to carry out real-time
quantitative RT-PCR analyses. The RT-qPCR validations were performed on the same sample
set as the microarray (#1H, #2H, #4G, #5G, #7GMu, #8GMu) and also on the third healthy dog
(#3H). To take account of the immunosuppressive context, we performed additional RT-qPCR
Fig 5. Impact of MuStem cell systemic delivery on GRMD dogmuscle. (A) False-colour heatmap illustrating the transcripts significantly differentially
expressed between GRMDMuStem dog and mock GRMD dog samples. Each line and column corresponds to a probe and an individual biological sample,
respectively. The gene names assigned to each probe are indicated on the right, separated by a comma in the case of multiple names as for example with
the myosin isoforms. The number of probes / genes are indicated beside each expression profile name. The standardized log2-transformed intensities are
plotted with a colour scale ranging from -2.50 (blue) to 2.50 (red) incremented by 0.25. (B) RT-qPCR validation of 15 genes. For each gene, fold change
values are indicated for GRMDMuStem dog versusGRMD dog. (C) Histograms of RT-qPCR for two selected genes: MUSTN1 and GPD1. Relative
quantifications (RQ) are calculated by normalizing with respect to RPS18.
doi:10.1371/journal.pone.0123336.g005
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experiments on muscle total RNA from two GRMDnonIS. Relative quantifications are calculated
for healthy, GRMDnonIS and mock GRMD dogs (S1 Table). GRMD dogs, whether or not im-
munosuppressed, show a similar variation of expression of the selected genes compared to
healthy dogs. This reinforces the microarray data on the GRMD dog model.
Then, to validate the molecular impact of MuStem cell transplantation, FC values are calcu-
lated GRMDMuStem versus GRMD dog comparison (Fig 5B). All of the genes further analysed
in this way show expression changes consistent with those estimated by gene chip analysis. In-
terestingly, the two samples from the same group yield closely similar relative quantifications
(RQ) for a given gene, as illustrated for the musculoskeletal embryonic nuclear protein 1
(MUSTN1) and the glycerol-3-phosphate dehydrogenase 1 (GPD1) genes (Fig 5C). In general,
RT-qPCR nevertheless yields slightly higher values than those obtained in the microarray
study, so this approach proves to be successful in validating microarray data.
Discussion
Over the last fifteen years, myoblasts and several stem cell populations including mesoangioblasts,
pericytes, CD133+ cells, PICs cells, Aldh+ cells, mesenchymal stem cells andMuscle-Derived
Stem Cells (MDSC), have been tested in different dystrophic or damaged muscles and defined as
having favourable engraftment properties and myogenic regenerative potential [42–50]. Interest-
ingly, some of these cells also exhibit an unexpected ability to migrate through vessels, leading us
to consider a whole-body distribution using systemic delivery [51]. As GRMD dogs represent a
large animal model having a pathogenesis very close to individuals with DMD, they are highly ap-
propriate for preclinical studies aiming to identify a new therapeutic product. In 2011, using this
clinically appropriate animal model, we showed that intra-arterial delivery of allogenic MuStem
cells, a sub-type of MDSC, resulted in a limitation in the development of muscle damage and a
long-term stabilization of the transplanted GRMD dog clinical status [29]. These data positioned
this population as a promising candidate for cell-based therapeutic development dedicated to
DMD. This persistent and generalized effect leads us to question the molecular impact of MuStem
cells; hence, in this study, we make use of a MuStem cell transplantation programme to develop
an expression profiling analysis, along with an investigation of the clinical and histological status.
In parallel with the first high-throughput characterization of GRMD dog muscle, our study pres-
ents, without prior assumptions, the molecular effects underlying the effect of MuStem cell
transplantation.
Pathophysiology of GRMD dog is defined by complex transcriptional
remodelling
Considering the state of the art in this field, we need to establish, at a transcriptomic level, a ref-
erenced set of deregulated genes involved in the pathophysiology of GRMD dog. We find that
up-regulated genes are significantly associated with genes bearing regeneration, regulation of
protein secretion as well as cell migration. Three other biological processes: extracellular matrix
organization, inflammatory response and cell adhesion, which are known as being modulated in
individuals with DMD [8,17], are significantly enriched in the identified differentially express-
ed genes. Furthermore, in accordance with the description of large caveolae observed in the
plasmic membrane of myocytes in GRMD dog [25], we observe an enrichment of themem-
brane-bounded vesicle term when comparing our GRMD samples with healthy dog samples. In
addition, down-regulated genes in GRMD dog muscle are over-represented in metabolic pro-
cesses, specifically involving the carboxylic acid catabolic process, regulation of transmembrane
transporter activity, fatty acid beta-oxidation, as well as oxidation-reduction and small-molecule
metabolic processes. These data are very well correlated with those previously obtained in
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individuals with DMD showing a differential gene profiling related to mitochondrial activity
[52]. Overall, we show an altered expression profile of 282 genes, including 117 genes previous-
ly identified as differentially expressed in individuals with DMD in at least one of the studies
concerned [8,9,11,12]. It is to notice that a limitation of the results presented here is that we
compare immunosuppressed GRMD dogs with healthy dogs that were not submitted to an im-
munosuppressive regimen. This means that in such a comparison we observe the effect of the
physiopathology associated with the effect of the immunosuppression known to impact the
GRMD dog phenotype [53,54]. Despite this, importantly, 98% of these 117 genes are similarly
differentially expressed in both GRMD dogs and individuals with DMD, and we show a signifi-
cant enrichment of up-regulated or down-regulated genes in both dog and human studies, con-
firming that our experimental design in GRMD dog is appropriate for the investigation of
DMD disease. These findings validate our strategy and also reinforce the evidence for molecu-
lar modifications observed after MuStem cell transplantation. Finally, our transcriptomic re-
sults obtained the first expression profile of GRMD dogs with an advanced age of 9 months
yield new informative data on the expression profile of dystrophic dog muscle, clearly illustrat-
ing that the consequences of the lack of dystrophin are multiple and associated with a profound
tissue remodelling, as shown by the involvement of a large number of biological processes.
MuStem cell administration enhances long-term skeletal muscle fibre
regeneration
In our previous study, we demonstrated that one of the consequences of MuStem cell systemic
delivery is histological remodelling, with a major increase in the muscle fibre regeneration ac-
tivity observed several weeks after cell delivery. The skeletal muscle samples from the dogs
used in the present study similarly show a striking increase in the proportion of newly formed/
regenerated muscle fibre, which is revealed by the expression of developmental myosin heavy
chain isoform in transplanted GRMD dog muscle four months after systemic administration.
This result highlights that transplanted MuStem cells actively contribute to persistent stimula-
tion of muscle fibre formation, as shown at the molecular level by the identification of up-regu-
lated genes including MUSNT1 (musculoskeletal embryonic nuclear protein1) and SPP1
(Secreted PhosphoProtein 1), which are implicated in myogenesis, regeneration and cell differ-
entiation. MUSNT1 is a key regulator of myogenic differentiation and fusion [55], and has
been shown to be up-regulated following the differentiation of porcine myoblasts into myo-
tubes [56]. Interestingly, the expression of this gene has been recently demonstrated in adult re-
generating skeletal muscle, activated satellite cells and differentiating myoblasts [57]. SPP1,
also named osteopontin, is an adhesive component of the extracellular matrix that also exists
as a soluble molecule. It is described as a key cytokine regulating tissue repair, inflammation
and fibrosis [58,59]. In injured muscle, SPP1 promotes macrophage binding to necrotic fibres,
and thus may be important in mediating the early phase of muscle regeneration [60]. More re-
cently, myoblasts have also been presented as an important source of SPP1 in damaged mus-
cles, where its release may assist in controlling both myogenic and inflammatory processes
during the early stages of muscle regeneration [61]. Concomitantly, we also find that develop-
mentally regulated genes, known to be transiently expressed during muscle development and
regeneration, such as ACTC1 (actin, alpha, cardiac muscle 1) and MYH3/MYH8 isoforms are
significantly up-regulated in the GRMDMuStem dog with advancing age. Interestingly, such en-
hanced expression of ACTC1, embryonic myosin heavy chain, versican, perinatal myosin
heavy chain, embryonic myosin light chain has also been documented in individuals with
DMD [9]. Lastly, we observe a decreased expression of the DEP domain containing MTOR-in-
teracting protein (DEPTOR), which is described to negatively regulate muscle proliferation
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and differentiation via the regulation of cell cycle regulatory proteins as well as muscle protein
synthesis [62]. The results of this transcriptome analysis collectively reveal for the first time a
molecular signature confirming the contribution of MuStem cells to muscle fibres regeneration
and repair.
MuStem cell administration enhances protein degradation in an
ubiquitin-dependent manner
The regulatory role of the ubiquitin proteasome system (UPS) ensures the clearance of dys-
functional or denatured proteins. In a muscular context, the UPS has been shown to have a
role in the mediation of skeletal muscle atrophy [63–65]. In a pathological context such as my-
opathy, skeletal muscle requires a rapid and efficient system for the removal of altered organ-
elles, the elimination of protein aggregates, and the disposal of toxic products that may lead to
cell death, thus allowing for the proper contraction of sarcomeres [66]. The UPS is thus in-
volved in protein quality control, and the two ubiquitin ligases atrogin-1 and MURF1, which
are associated with autophagy-lysosome systems, can ensure the rapid elimination of single
proteins or small aggregates [67–69]. Autophagy is required for cellular survival, and this new
concept changes the current view that proteolysis is detrimental; the new vision is to consider
transitory activation of the proteolytic systems to eliminate misfolded muscle proteins in my-
opathy [69]. In human heart failure syndromes, recent evidence supports a role for protein
damage and impaired clearance of damaged proteins in the pathology, and highlights the UPS
as the primary effector of regulatory control [70]. In the present study, we show that MuStem
cell transplantation stimulates the expression of several genes involved in the protein degrada-
tion machinery via this system. Specifically, FBXO32 (Atrogin 1), TRIM63 (MURF1),
ZFAND5 and MT2A encode proteins of the E3 ubiquitin ligase complex, which mediates the
ubiquitination, and subsequent proteasomal degradation of target proteins. This suggests that
muscle tissue remodelling resulting from MuStem cell transplantation may involve preliminary
UPS proteins and associated proteins such as metallothioneins in order to clear misfolded pro-
teins. These latter could be toxic to myogenic cells, and have to be eliminated prior to efficient
muscle fibre formation. After MuStem cell transplantation, a reversal is observed in the expres-
sion level of the subunit LMP-2 (PSMB9 gene), which is significantly up-regulated in GRMD
dog as compared to healthy dog, strongly suggesting that protein degradation required for skel-
etal muscle regeneration is mainly mediated in an ubiquitin-dependent manner.
MuStem cell administration induces insulin resistance in skeletal muscle
Based on under-representation of several key enzymes that control both glycolytic and oxida-
tive metabolism, we have previously shown a dramatic alteration of metabolic proteins in
GRMD dog versus healthy dog [6]. Skeletal muscle is responsible for 70 to 80% of whole body
uptake, disposal, and storage of insulin-stimulated glucose. Therefore, we consider that skeletal
muscle plays a major role in energy balance. Furthermore, skeletal muscle has an influence on
the metabolism and storage of lipids and plays an important role in hormone signalling [71].
Insulin resistance in adipocytes induced by TNFα is accompanied by an increased GM3 bio-
synthesis through the up-regulation of GM3 synthase (ST3GAL5) gene expression [72]. In the
present study, we find that the level of GM3 synthase mRNA is significantly higher in GRMD
dog muscle than in healthy dog, possibly reflecting adipose tissue infiltration and, more gener-
ally, the participation of GM3 synthesis in abnormal insulin resistance in GRMD dog. It is in-
teresting to note that, after MuStem cell transplantation, skeletal muscle is characterized by a
reversal in the expression level of ST3GAL5, which could represent the molecular hallmark of a
decrease in infiltrating adipose tissue, triglyceride synthesis and an improved insulin signalling
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after cell transplantation [73]. This hypothesis is supported by the fact that, similarly, the ex-
pression of Glycerol-3-phosphate dehydrogenase 1 (GPD1), equally involved in insulin metab-
olism, is significantly decreased in GRMDMuStem.
Muscle glycogen accumulation results from the disruption of the insulin pathway influenc-
ing glucose metabolism and transport, and has been demonstrated inmdxmice [74] and indi-
viduals with DMD [75,76]. Such accumulation is accompanied by elevated glycogen synthase
activity and protein expression. In a previous proteomic study performed on GRMD dog mus-
cle, we observed an increased level of protein phosphatase 1 (PP1) concomitantly with a de-
crease in the level of its major deactivator, glycogen synthase kinase (GSK)-3β [26]. Consistent
with this result, we demonstrate the down-expression in GRMDMuStem dog muscle of both
genes encoding the proteins PP1R3B (Protein Phosphatase 1, regulatory subunit 3B) and
PVALB (parvalbumin) that are involved in glycogen synthesis. These genes belong to the same
regulatory network as the muscular adiponectin (ADIPOQ), which is known to regulate glu-
cose and fatty acid metabolism both directly and via insulin sensitizing effects [77]. Also, it is
proposed that its up-regulation probably reflects adipose tissue infiltration [78]. Here, we ob-
serve a significant over-expression of this gene in GRMD dog muscle, followed by a slight ten-
dency to decreased gene expression four months after MuStem cell transplantation, which is
confirmed by RT-qPCR. Since adiponectin elicits important functional effects on skeletal mus-
cle [79] and can generate beneficial metabolic effects, as recently established in diabetes [80],
while its local production is also associated with increased insulin sensitivity [81], further ex-
periments need to be performed to refine the role of MuStem cells in the adiponectin-depen-
dent regulatory pathway. Overall, these new molecular results give compelling evidence
suggesting that MuStem cells influence insulin resistance and glucose and fatty acid metabo-
lism in GRMD dog muscle.
MuStem cell administration causes a lower requirement of creatine
synthesis
L-arginine:glycine amidinotransferase (GATM or AGAT) is a mitochondrial enzyme that be-
longs to the amidinotransferase family and catalyzes the first step of creatine synthesis. It is in-
volved in many metabolic (threonine, serine, arginine, proline) pathways, in creatine
biosynthesis and in tissue regeneration [82]. GATM was found to be up-regulated inmdx
mice, and it has been proposed that the up-regulation of the creatine synthetic pathway may
help maintaining muscle creatine levels and limiting cellular energy failure inmdx skeletal
muscles [83]. Among the differentially expressed genes identified herein, GATM exhibits an
up-expression in GRMDmuscle that could directly point out depletion of the muscle creatine
pool occurring in highly and continuously remodeling muscle tissue. Interestingly, a 2-fold de-
crease was determined four months after MuStem cell transplantation, based on independent
analysis of three probes. Then, GATM expression level is similar to the one in the healthy dog
muscle. This could evoke a lower requirement of creatine synthesis correlated to a better tissue
organization following an increased regeneration of muscle fibre.
Conclusions
In summary, this study shows for the first time the effect of an adult stem cell transplantation
on skeletal muscle gene expression in a DMD-like context. Interestingly, our results clearly re-
flect that MuStem cells impact many biological processes several months after their transplan-
tation that could explain the beneficial effect on dystrophic phenotype of GRMDMuStem dogs.
Among these effects, gene expression profiling demonstrated an ability to maintain an intense
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muscle fibre regeneration activity that may play an essential role in stabilization of muscle
tissue phenotype.
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S1 Fig. Weight curve and biochemical parameters of GRMD and GRMDMuStem dogs. Dogs
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nase (CK), urea, creatinine, alkaline phosphatase (ALP) and alanine aminotransferase (ALT)
were determined for GRMD dogs (#4G to #6G) and GRMDMuStem dogs (#7GMu to #10GMu).
Dogs that received MuStem cell transplantation are shown in grey. References values were ob-
tained from Oniris (Nantes, France). #Dogs are not yet under immunosuppression at this
time point.
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S2 Fig. Dystrophin expression profile in supplementary GRMDMuStem dog muscle samples.
Transverse cryosections of the Biceps femorismuscle of 9-month-old healthy (A) #2H, GRMD
(B) #5G and additional GRMDMuStem dogs (C-E; #9GMu, #8GMu and #10GMu respectively).
Scale bar = 200 μm.
(TIF)
S3 Fig. Combined Dystrophin immunolabelling and nuclear counterstaining. The first
panel is a bright field image (A-C). Dystrophin expression in healthy (D), mock GRMD (E)
#5G and GRMDMuStem (F) #9GMu dogs. Nuclear counterstaining is shown in red. Scale
bar = 200 μm.
(TIFF)
S4 Fig. Total RNA and microarray data quality controls. (A) Total RNA electropherograms.
The RNA integrity numbers (RIN) are calculated for each sample. (B) Distribution of the log2-
transformed signal intensities of the duplicate healthy, GRMD and GRMDMuStem dog samples
before normalization. (C) Distance matrix of normalized expression data. The similarity be-
tween samples are colour-coded from white for the identity to black for the most dissimilar, al-
lowing a clustering of the samples according to the dendrogram represented at the top and on
the left.
(EPS)
S1 File. The file summarizes the 608 probes identified as differentially expressed in this
study. Several types of information such as gene name, annotation and classification are avail-
able, as well as comparisons with other human studies. Normalized and log2-transformed ex-
pression data are given for individual dog samples and averaged for healthy, GRMD and
GRMDMuStem groups.
(XLSX)
S2 File. The file contains the results of the Gene Ontology enrichment analysis for the
group of genes differentially expressed in the GRMD sample as compared to the healthy
dogs. “n” represents the total number of genes assigned using the Gene Ontology terms and
in the considered group of genes. “nEXP” corresponds to the number of genes expected by
chance.
(XLSX)
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S1 Table. RT-qPCR values of the 15 selected genes for healthy, non-immunosuppressed
GRMD (GRMDnonIS) and GRMD dogs.
(PDF)
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